Replies to post #36166 on Amarantus Bioscience Holdings Inc (AMBS)

[duelittle2]

" MANF has the commercial potential to become a blockbuster drug."

"Dr. Joseph Rubinfeld, co-founder of Amgen, stated "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson's, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug."

Amarantus is also a recipient of a grant from the Michael J Fox Foundation.

http://seekingalpha.com/article/1016221-finding-a-cure-for-parkinson-s